Last €4.00 EUR
Change Today +0.01 / 0.25%
Volume 4.0K
ALTER On Other Exchanges
Symbol
Exchange
EN Paris
As of 4:11 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

theradiag (ALTER) Snapshot

Open
€4.00
Previous Close
€3.99
Day High
€4.04
Day Low
€4.00
52 Week High
02/27/14 - €9.30
52 Week Low
12/13/13 - €3.18
Market Cap
17.9M
Average Volume 10 Days
13.0K
EPS TTM
--
Shares Outstanding
4.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THERADIAG (ALTER)

Related News

No related news articles were found.

theradiag (ALTER) Related Businessweek News

No Related Businessweek News Found

theradiag (ALTER) Details

Theradiag SA develops, produces, and markets in vitro diagnostics products in France and internationally. It offers auto-immunity products, such as FIDIS kits that allow detection of multiple analytes from the same sample in a single assay; immunofluorescence tests to screen and identify the auto-antibodies; ELISA tests for performing various tests on the same plate; Chorus systems that are compact multi-parametric analyzers; and immunoblot tests, which allow simultaneous detection of antibodies. The company also provides genetic tests comprising AmplideX products line for the diagnosis of the Fragile X syndrome; xTAG Gastrointestinal Pathogens Panel kits for identifying various gastrointestinal pathogens; xTAG Respiratory Viral Panel kits for identification of common respiratory viruses; and BCR/ABL1 Quant tests that are in vitro diagnostic products, as well as Signature kits. In addition, it offers CLA Optigen 30, an in vitro test for the diagnosis of allergy conditions; a panel of reagents for identifying the type of infectious diseases, such as bacteriology, virology, and parasitology; and Immunochromatographic rapid tests for the detection of drugs. Further, the company provides SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos to the computer; OCTEIA 25-Hydroxy Vitamin D kit intended to assay 25-Hydroxy vitamin D and other hydroxylated metabolites present in human serum or plasma; and Serum CrossLaps ELISA kits for the immunoenzyme assay of a specific C-terminal sequence for type I collagen in human serum and plasma, as well as CER F 820001F for analyzing small amounts of hemoglobin in feces. Additionally, it offers a range of instruments, including CARIS, e-Robot, FIDIS, and Chorus instruments for diagnosing auto-immunity and infectious diseases. The company also offers Lisa-Tracker kits for monitoring the treatment of patients treated by anti-TNFa. The company was founded in 1986 and is based in Marne-la-Vallée, France.

65 Employees
Last Reported Date: 09/23/14
Founded in 1986

theradiag (ALTER) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

theradiag (ALTER) Key Developments

THERADIAG Announces Monitoring of Biotherapeutic Treatments of Crohn's Disease Could Produce Savings of More Than EUR 130 Million in France

THERADIAG announced the results of a pharmaco-economic report which demonstrates that the use of anti-TNF monitoring and anti-TNF antibodies in the treatment of patients with Crohn's disease treated by biotherapies can save up to 25% of the cost of treatment, or EUR 131 million over 5 years in France alone. Anti-TNF: a widely used range of biotherapies with established efficacy, but which can frequently be unsuitable and costly. Diseases related to immune system disorders, such as rheumatoid arthritis, ankylosing spondylitis and inflammatory bowel disease, are chronic pathologies which affect more than 28 million people around the world. Biotherapies, frequently trigger immune responses from the patient, leading to treatment loss of response. There is a need for therapeutic drug monitoring to allow clinicians to assess patient responses in order to anticipate, optimize and change treatment. Given the ever more frequent use of anti-TNF treatments (in France, around 85,000 patients are treated with Anti-TNF alpha including 30,000 inflammatory bowel diseases patients), their cost (of EUR 14,000 to EUR 16,000 per patient per year) and the severity of the diseases concerned, it seems essential to rationalize their use so as to gain greater control over their cost. The study looked at a double cohort of patients (3,000 and 10,000) suffering from Crohn's disease and treated with anti-TNF over a given period (1, 3 and 5 years). It was run by Professors Duru (Honorary Research Director at CNRS) and Lamure (Professor at University Claude Bernard, Lyon), who were responsible for the methodology, and three experts in gastroenterology: Dr. Attar (Hôpital Beaujon, Clichy), Professor Peyrin-Biroulet (CHU, Nancy) and Professor Roblin (CHU, Saint-Etienne).

THERADIAG Reports Consolidated Earnings Results for the Half-Year Ended June 30, 2014

THERADIAG reported consolidated earnings results for the half-year ended June 30, 2014. For the period, the company reported sales of EUR 3,374,000 compared to EUR 3,544,000 a year ago. Operating loss was EUR 1,630,000 compared to EUR 1,045,000 a year ago. Pre-tax loss was EUR 1,694,000 compared to EUR 1,056,000 a year ago. Net loss was EUR 1,432,000 compared to EUR 884,000 a year ago.

Theradiag Announces the Launch of the Second Phase of its Study to Identify microRNA Biomarkers

Theradiag announced the launch of the second phase of its study to identify microRNA biomarkers to predict the response to treatment and metastatic relapse in rectal cancer. Biological validation will be carried out on a broader range of patients, in partnership with the Regional Cancer Institute of Montpellier. The first phase of the miCRA project began at the end of 2013 with the screening of potential microRNA candidates, which was followed by a technical validation on an initial cohort of 70. A biostatistical analysis of the data has helped identify modulated and specific microRNA candidates that predict the response to chemo/radiotherapy treatments and metastatic recurrence in rectal cancer. The aim of the second phase of this study will be to validate, across a broader range of patients, the biological relevance of the identified microRNA candidates in order to establish a robust signature that could be routinely used in a new theranostics test. This second phase is also being carried out in partnership with the ICM.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALTER:FP €4.00 EUR +0.01

ALTER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALTER.
View Industry Companies
 

Industry Analysis

ALTER

Industry Average

Valuation ALTER Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERADIAG, please visit www.theradiag.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.